Zhou Shuguang, Wang Bing, Hu Jun, Zhou Yucheng, Jiang Mengzhen, Wu Mingyu, Qin Liming, Yang Xuming
Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha, 410011, Hunan, China.
Department of Orthopedics, The Affiliated Hospital of Hunan University of Medicine and The Third People's Hospital of Huaihua, Huaihua, 418000, Hunan, China.
Tumour Biol. 2016 Jul;37(7):9001-7. doi: 10.1007/s13277-015-4578-5. Epub 2016 Jan 13.
MicroRNAs (miRNAs) are a new class of prognostic and diagnostic biomarkers for many cancers. Recent studies have shown that miRNAs are highly stable in plasma/serum. The aim of this study was to investigate the role of miR-421 in osteosarcoma. We found that the serum expression levels of miR-421 were significantly higher in osteosarcoma patients than those in healthy volunteers. Moreover, miR-421 expression was significantly higher in osteosarcoma tissues compared with that in the adjacent normal tissues. Meanwhile, the expression of miR-421 was upregulated in 90 % (36/40) osteosarcoma tissues compared to non-tumor tissues. More importantly, the expression levels of miR-421 in osteosarcoma tissues were correlated with those in patients' serum. In addition, patients with high miR-421 expression had shorter overall survival (OS) than those with low expressions. We also found that overexpression of miR-421 promoted osteosarcoma cell line MG-63 proliferation, migration, and invasion. In conclusion, miR-421 expression levels were upregulated in osteosarcoma tissue and serum and it may be a useful marker for diagnosis of osteosarcoma.
微小RNA(miRNA)是许多癌症新的预后和诊断生物标志物。最近的研究表明,miRNA在血浆/血清中高度稳定。本研究的目的是探讨miR-421在骨肉瘤中的作用。我们发现,骨肉瘤患者血清中miR-421的表达水平显著高于健康志愿者。此外,与相邻正常组织相比,miR-421在骨肉瘤组织中的表达明显更高。同时,与非肿瘤组织相比,90%(36/40)的骨肉瘤组织中miR-421的表达上调。更重要的是,骨肉瘤组织中miR-421的表达水平与患者血清中的表达水平相关。此外,miR-421高表达的患者总生存期(OS)比低表达患者短。我们还发现,miR-421的过表达促进了骨肉瘤细胞系MG-63的增殖、迁移和侵袭。总之,骨肉瘤组织和血清中miR-421的表达水平上调,它可能是骨肉瘤诊断的有用标志物。
Tumour Biol. 2016-7
Biomed Pharmacother. 2015-9-28
Int J Clin Oncol. 2019-5-20
Cancer Biother Radiopharm. 2020-6
Cancer Biomark. 2018
Biomed Pharmacother. 2016-10-8
Int J Clin Oncol. 2025-7-18
NPJ Precis Oncol. 2024-8-3
Int J Mol Sci. 2023-8-28
Front Endocrinol (Lausanne). 2023
Cancer Drug Resist. 2022-6-21
Int J Clin Exp Pathol. 2015-1-1
Cell Prolif. 2015-6
Cell Prolif. 2015-6
Biochem Biophys Res Commun. 2015-4-10
Cell Prolif. 2014-12-22
J Surg Res. 2015-4
Int J Clin Exp Pathol. 2014-6-15